Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
0(0%)
Results Posted
50%(1 trials)
Terminated
1(20%)

Phase Distribution

Ph phase_1
1
20%
Ph phase_4
3
60%

Phase Distribution

1

Early Stage

0

Mid Stage

3

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 4Post-market surveillance
3(75.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(2)
Terminated(1)
Other(2)

Detailed Status

unknown2
Completed2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
66.7%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (25.0%)
Phase 43 (75.0%)

Trials by Status

unknown240%
completed240%
terminated120%

Recent Activity

0 active trials
Showing 5 of 5
completedphase_4

Pegaptanib for Retinal Edema Secondary to Diabetic Vascular Disease(Preserve) Study

NCT01486238
unknown

A Single-Center Trial of High Frequency Pegaptanib for Rapid Restoration of VEGF Levels in Diabetic Retinal Edema

NCT01487044
completedphase_1

A Single-Center Trial of Intravitreous Injections of Macugen (Pegaptanib Sodium) Given at Least 7 Days Before Vitrectomy Secondary To Tractional Retinal Detachment in Proliferative Diabetic Retinopathy

NCT01487070
unknownphase_4

Macugen for Proliferative Diabetic Retinopathy Study With Extended Dosing (M-PDRS ED)

NCT01486771
terminatedphase_4

Macugen (Pegaptanib Sodium) Alone, Versus Macugen in Combination With PDT (Photodynamic Therapy) With Visudyne (Verteporfin) in Patients With Age-Related Macular Degeneration (AMD)

NCT00134667

Clinical Trials (5)

Showing 5 of 5 trials
NCT01486238Phase 4

Pegaptanib for Retinal Edema Secondary to Diabetic Vascular Disease(Preserve) Study

Completed
NCT01487044

A Single-Center Trial of High Frequency Pegaptanib for Rapid Restoration of VEGF Levels in Diabetic Retinal Edema

Unknown
NCT01487070Phase 1

A Single-Center Trial of Intravitreous Injections of Macugen (Pegaptanib Sodium) Given at Least 7 Days Before Vitrectomy Secondary To Tractional Retinal Detachment in Proliferative Diabetic Retinopathy

Completed
NCT01486771Phase 4

Macugen for Proliferative Diabetic Retinopathy Study With Extended Dosing (M-PDRS ED)

Unknown
NCT00134667Phase 4

Macugen (Pegaptanib Sodium) Alone, Versus Macugen in Combination With PDT (Photodynamic Therapy) With Visudyne (Verteporfin) in Patients With Age-Related Macular Degeneration (AMD)

Terminated

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5